11 Most Promising Long-Term Stocks According to Analysts

Page 10 of 10

1. Sarepta Therapeutics Inc. (NASDAQ:SRPT)

10-Year Revenue CAGR: 69.43%

Number of Hedge Fund Holders: 50

Average Upside Potential as of April 21: 230.92%

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that discovers and develops RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It has collaboration and license agreements with several companies and institutions.

ELEVIDYS is Sarepta’s gene therapy for Duchenne Muscular Dystrophy. In Q4 2024 alone, ELEVIDYS sales reached $384.2 million, which was a sequential improvement of 112%. The company projects ELEVIDYS to improve by over 160% year-over-year in 2025 and make up ~two-thirds of Sarepta’s total net product revenue guidance. Since its approval in 2023, ELEVIDYS has made over $1 billion in sales. This figure is still less than 5% of the on-label addressable patient opportunity.

The recent positive two-year and one-year crossover results from the EMBARK trial further solidify the therapy’s transformative potential. With 600+ patients now on therapy across a range of ages and weights, Sarepta Therapeutics Inc. (NASDAQ:SRPT) is expanding its global reach and improving manufacturing efficiency.

While we acknowledge the growth potential of Sarepta Therapeutics Inc. (NASDAQ:SRPT), our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than SRPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 10 of 10